Are lower MRPs on cancer drugs translating into affordable care?
The Hindu · Bindu Shajan Perappadan ·
National Pharmaceutical Pricing Authority (NPPA) has capped trade margins at 30% for 137 non-scheduled anti-cancer drugs, reducing the price of nearly 900 cancer medicine brands by up to 70%-93%. However, for comprehensive cancer care in India, price regulation might not be enough.
In a move to make cancer treatment more affordable, the National Pharmaceutical Pricing Authority (NPPA) has capped trade margins at 30% for 137 non-scheduled anti-cancer drugs, reducing the price of nearly 900 cancer medicine brands by up to 70%-93%. However, for comprehensive cancer care in India, price regulation might not be enough. Are lower MRPs on cancer drugs translating into affordable care? Indu Bhushan and K.M. Gopakumar discuss the question in a conversation moderated by Bindu Shajan Perappadan. Indu Bhushan is bureaucrat, economist and the first CEO of Ayushman Bharat; K.M. Gopakumar is legal adviser, senior researcher and public health expert
Read the full story at The Hindu · All coverage of this story